Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing KIMMTRAK®(tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma in light of its recent FDA approval.

Ticker(s): IMCR

Who's the expert?

Institution: Self-Employed

Board-certified ophthalmologist and award-winning retinal specialist, Medical Director for the Macular Degeneration Association (MDA) and Founder & CEO of Mali Enterprises
manages 2,000 patients with GA and utilizes the most advanced surgical techniques and technology in the world to deliver the highest quality retinal surgery for his patients
Interested in new treatments for wet macular degeneration, diabetic retinopathy, and uveitis.

Interview Goal

The ideal expert will be knowledgeable about the potential of KIMMTRAK as the first T cell receptor (TCR) therapeutic to receive regulatory approval and familiar with the press releases and clinical trial data surrounding KIMMTRAK. We would like to discuss the potential of this novel therapeutic in the ophthalmology space.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.